

Donors: [Log In](#) or [Sign Up](#) for myGiving



[Request an appointment](#)

Home » Education & Research



Xifeng Wu

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Epidemiology, Division of OVP,
Cancer Prevention and Population Sciences, The University of
Texas MD Anderson Cancer Center, Houston, TX

Director, Center for Translational and Public Health Genomics, The
University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Epidemiology, Division of Cancer
Prevention and Population Sciences, The University of Texas MD
Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Division of Epidemiology, Human Genetics and
Environmental Sciences, The University of Texas School of Public
Health, Houston, TX

Bio Statement

My major area of interest is using a molecular epidemiological approach to develop and validate genetic biomarkers for cancer risk assessment and for clinical outcome prediction via a variety of epidemiologic and molecular techniques (including genetics, epigenetics, cytogenetics, and computational biology). I am the principle investigator of multiple large NCI funded epidemiologic projects. We are applying candidate gene and genome-wide scanning approaches to identify cancer susceptibility loci and germline genetic predictors of clinical outcomes. We have developed or adapted an array of phenotypic assays in population studies (including but not limited to mutagen sensitivity assay for latent genetic instability, Comet assay and host-cell reactivation assay for DNA repair capacity, interphase FISH to identify hotspots for DNA damage, quantitative FISH to measure telomere length, mitochondrial DNA deletion and copy number changes, and global hypermethylation). We are also applying a variety of high-throughput genome-wide approaches, such as SNP-array CGH, gene expression array, microRNA array, and methylation array, to profile genetic and biological changes in premalignant and malignant somatic tissues. The long term goal of my research is to incorporate epidemiological, clinical, and genetic (germline and/or somatic) information to develop personalized risk prediction models for cancer etiology and clinical outcomes, for example, my group developed the first basic and enhanced bladder cancer risk prediction model. My research team is multi-disciplinary with diverse expertise in molecular biology, genetics, epidemiology, and statistics. I have an excellent track record of training students, post-docs, clinical fellows, and junior faculties and many of them have got independent tenure-track faculty positions.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Herman P. Pressler Blvd.
Unit Number: 1340
Houston, TX 77030
Room Number: CPB4.3301
Phone: (713) 745-2485
Fax: (713) 792-4657
Email: xwu@mdanderson.org

Education & Training

1994	The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, PHD, Epidemiology
1987	Zhejiang University, Hangzhou, China, MS, Industrial Hygiene and Occupational Diseases
1984	Fudan University, Shanghai, China, MD, Medicine

Experience/Service

Institutional Committee Activities

Member, Bladder Cancer SPORE Executive Committee,
2002-present

Honors and Awards

2012-present	Wall of Science Publication Gallery Inclusion, The University of Texas MD Anderson Cancer Center
2011	Robert M. Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center
2008-present	Senior Fellow of the MD Anderson Research Trust, The University of Texas MD Anderson Cancer Center

Selected Publications

Peer-Reviewed Original Research Articles	
1.	He Y, Gong Y, Lin J, Chang DW, Gu J, Roth JA, Wu X . Ionizing radiation-induced γ -H2AX activity in whole blood culture and the risk of lung cancer. <i>Cancer Epidemiol Biomarkers Prev</i> . e-Pub 1/8/2013. PMID: 23300022.
2.	Ye Y, Madison B, Wu X, Rustgi AK . A LIN28B polymorphism predicts for colon cancer survival. <i>Cancer Biol Ther</i> 13(14):1390-5, 12/1/2012. e-Pub 10/10/2012. PMCID: PMC3542229.
3.	Zhang N, Wu X, Yang L, Xiao F, Zhang H, Zhou A, Huang Z, Huang S . FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51. <i>Clin Cancer Res</i> 18(21):5961-71, 11/1/2012. e-Pub 9/12/2012. PMID: 22977194.
4.	Reyes-Gibby CC, Wang J, Spitz M, Wu X, Yennurajalingam S, Shete S . Genetic Variations in Interleukin-8 and Interleukin-10 are Associated With Pain, Depressed Mood, and Fatigue in Lung Cancer Patients. <i>J Pain Symptom Manage</i> . e-Pub 11/10/2012. PMID: 23149083.
5.	Wilkinson AV, Gabriel KP, Wang J, Bondy ML, Dong O, Wu X, Shete S, Spitz MR . Sensation seeking genes and physical activity in youth. <i>Genes Brain Behav</i> . e-Pub 11/28/2012. PMID: 23190435.
6.	Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, Huang M, Hsu CY, Ye Y, Mishra L, Hawk E, Wu X . Hepatocellular Carcinoma Risk Prediction Model for the General Population: The Predictive Power of Transaminases. <i>J Natl Cancer Inst</i> 104(20):1599-611, 10/17/2012. PMID: 23073549.
7.	Gu J, Wang Y, Wu X . MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer. <i>Curr Pharm Des</i> . e-Pub 9/25/2012. PMID: 23092349.
8.	Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman SM, Hildebrandt MA, Hong WK, Minna JD, Roth JA, Yang P, Wu X . Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. <i>Clin Cancer Res</i> . e-Pub 9/13/2012. PMID: 22977190.
9.	Timofeeva MN, Hung RJ, Rafnar T, Christiani DC, Field JK, Bickeboller H, Risch A, McKay JD, Wang Y, Dai J, Gaborieau V, McLaughlin J, Brenner D, Narod S, Caporaso NE, Albanes D, Thun M, Eisen T, Wichmann HE, Rosenberger A, Han Y, Chen W, Zhu D, Spitz M, Wu X, Pande M, Zhao Y .

- [C, Vatten L, Njølstad L, Chen C, Goodman G, Lathrop M, Benhamou S, Vooger T, Völk K, Nelis M, Metspalu A, Raji O, Chen Y, Gosney J, Liloglou T, Muley T, Dienemann H, Thorleifsson G, Shen H, Stefansson K, Brennan P, Amos CI, Houlston R, Landi MT, for TRICL Research Team](#). Influence of Common Genetic Variation on Lung Cancer Risk: Meta-Analysis of 14,900 Cases and 29,485 Controls. *Hum Mol Genet*. e-Pub 8/2012. PMID: 22899653.
10. [Lin J, Lu C, Stewart DJ, Gu J, Huang M, Chang DW, Lippman SM, Wu X](#). Systematic Evaluation of Apoptotic Pathway Gene Polymorphisms and Lung Cancer Risk. *Carcinogenesis*. e-Pub 8/2012. PMID: 22665367.
 11. [Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X](#). Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients. *Clin Cancer Res* 18(14):3982-91, 7/2012. e-Pub 6/2012. PMID: 22661538.
 12. [Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X](#). Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention. *Clin Cancer Res* 18(13):3705-13, 7/2012. e-Pub 5/2012. PMCID: PMC3404728.
 13. [Chang DW, Gu J, Wu X](#). Germline prognostic markers for urinary bladder cancer: Obstacles and opportunities. *Urol Oncol* 30(4):524-32, 7/2012. PMID: 22742565.
 14. [Spitz MR, Gorlov IP, Dong Q, Wu X, Chen W, Chang DW, Etzel CJ, Caporaso NE, Zhao Y, Christiani DC, Brennan P, Albanes D, Shi J, Thun M, Landi MT, Amos CI](#). Multistage Analysis of Variants in the Inflammation Pathway and Lung Cancer Risk in Smokers. *Cancer Epidemiol Biomarkers Prev* 21(7):1213-21, 7/2012. e-Pub 5/2012. PMID: 22573796.
 15. [Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L](#). Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol*. e-Pub 6/2012. PMID: 22710573.
 16. [Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, Ellis LM, Wu X](#). Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. *Cancer*. e-Pub 6/2012. PMID: 22673945.
 17. [Lin M, Eng C, Hawk ET, Huang M, Greisinger AJ, Gu J, Ellis LM, Wu X, Lin J](#). Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. *Carcinogenesis* 33(4):841-7, 4/2012. e-Pub 2/2012. PMCID: PMC3324446.
 18. [Hildebrandt MA, Tan W, Tamboli P, Huang M, Ye Y, Lin J, Lee JS, Wood CG, Wu X](#). Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients. *Carcinogenesis* 33(4):799-803, 4/2012. e-Pub 1/2012. PMCID: PMC3324439.
 19. [Fu YP, Kohaar J, Rothman N, Earl J, Figueroa JD, Ye Y, Malats N, Tang W, Liu L, Garcia-Closas M, Muchmore B, Chatterjee N, Tarway M, Kogevinas M, Porter-Gill P, Baris D, Mumy A, Albanes D, Purdue MP, Hutchinson A, Carrato A, Tardon A, Serra C, Garcia-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Diver WR, Gapstur SM, Thun MJ, Virtamo J, Chanock SJ, Fraumeni JE, Silverman DT, Wu X, Real FX, Prokunina-Olsson L](#). Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. *Proc Natl Acad Sci U S A* 109(13):4974-9, 3/2012. e-Pub 3/2012. PMCID: PMC3324016.
 20. [Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP](#). Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. *J Urol* 187(3):862-7, 3/2012. e-Pub 1/2012. PMCID: PMC3278506.
 21. [Wagner KW, Ye Y, Lin J, Vaporciyan AA, Roth JA, Wu X](#). Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non-Small Cell Lung Cancer Patients. *Clin Cancer Res* 18(2):585-92, 1/2012. PMID: 22252258.

bladder cancer risk. *Int J Cancer*. e-Pub 1/2012. PMID: 22201697.

23. [Wei H, Kamat A, Chen M, Ke HL, Chang DW, Yin J, Grossman HB, Dinney CP, Wu X](#). Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with bacillus calmette-guérin. *PLoS One* 7(6):e38533, 2012. e-Pub 6/2012. PMCID: PMC3373532.
24. [Chang J, Dinney CP, Huang M, Wu X, Gu J](#). Genetic variants in telomere-maintenance genes and bladder cancer risk. *PLoS One* 7(2):e30665, 2012. e-Pub 2/2012. PMCID: PMC3281862.
25. [Wang J, Spitz MR, Amos CI, Wu X, Wetter DW, Cinciripini PM, Shete S](#). Method for Evaluating Multiple Mediators: Mediating Effects of Smoking and COPD on the Association between the CHRNA5-A3 Variant and Lung Cancer Risk. *PLoS One* 7(10):e47705, 2012. e-Pub 10/15/2012. PMCID: PMC3471886.
26. [Wei C, Han Y, Spitz MR, Wu X, Chancoco H, Akiva P, Rechavi G, Brand H, Wun I, Frazier ML, Amos CI](#). A Case-Control Study of a Sex-Specific Association between a 15q25 Variant and Lung Cancer Risk. *Cancer Epidemiol Biomarkers Prev*. e-Pub 11/2011. PMID: 22028403.
27. [Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, Wang Z, Zelenika D, Moore LE, Wood CG, Prokhorov E, Gaborieau V, Jacobs KB, Chow WH, Toro JR, Zaridze D, Lin J, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Jirga V, Bencko V, Slamon A, Holcatova I, Navratilova M, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Virtamo J, Vatten L, Hveem K, Fletcher T, Koppova K, Cussenot O, Cancel-Tassin G, Benhamou S, Hildebrandt MA, Pu X, Foglio M, Lechner D, Hutchinson A, Yeager M, Fraumeni JF, Lathrop M, Skryabin KG, McKay JD, Gu J, Brennan P, Chanock SJ](#). A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. *Hum Mol Genet*. e-Pub 11/2011. PMID: 22010048.
28. [Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB, Baris D, Thun M, De Vivo I, Albanes D, Purdue MP, Kogevinas M, Kamat AM, Lerner SP, Barton Grossman H, Gu J, Pu X, Hutchinson A, Fu YP, Burdett L, Yeager M, Tang W, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Ryan Diver W, Gapstur SM, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Teresa Landi M, Fraumeni JF, Silverman DT, Chanock SJ, Wu X](#). A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. *Hum Mol Genet* 20(21):4282-9, 11/2011. e-Pub 8/2011. PMCID: PMC3188994.
29. [Wilkinson AV, Bondy ML, Wu X, Wang J, Dong Q, D'Amelio AM, Prokhorov AV, Pu X, Yu RK, Etzel CJ, Shete S, Spitz MR](#). Cigarette Experimentation in Mexican Origin Youth: Psychosocial and Genetic Determinants. *Cancer Epidemiol Biomarkers Prev*. e-Pub 11/2011. PMID: 22028400.
30. [Tan W, Hildebrandt MA, Pu X, Huang M, Lin J, Matin SF, Tamboli P, Wood CG, Wu X](#). Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes. *J Urol* 186(5):2071-7, 11/2011. e-Pub 9/2011. PMID: 21944129.
31. [Lin M, Stewart DJ, Spitz MR, Hildebrandt MA, Lu C, Lin J, Gu J, Huang M, Lippman SM, Wu X](#). Genetic variations in the transforming growth factor beta pathway as predictors of survival in advanced non-small cell lung cancer. *Carcinogenesis* 32(7):1050-6, 7/2011. e-Pub 4/2011. PMCID: PMC3128559.
32. [Gu J, Chen M, Shete S, Amos CI, Kamat A, Ye Y, Lin J, Dinney CP, Wu X](#). A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. *Cancer Prev Res (Phila)* 4(4):514-21, 4/2011. e-Pub 4/2011.

- Genetic Variants in TGF- β Pathway Are Associated with Ovarian Cancer Risk. PLoS One 6(9):e25559, 2011. e-Pub 9/2011. PMCID: PMC3184159.
34. [Yoon HH](#), [Catalano PJ](#), [Murphy KM](#), [Skaar TC](#), [Philips S](#), [Powell M](#), [Montgomery EA](#), [Hafez MJ](#), [Offer SM](#), [Liu G](#), [Meltzer SJ](#), [Wu X](#), [Forastiere AA](#), [Benson AB](#), [Kleinberg LR](#), [Gibson MK](#). Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer 11(1):176, 2011. e-Pub 5/2011. PMCID: PMC3118194.
35. [Dai J](#), [Gu J](#), [Lu C](#), [Lin J](#), [Stewart D](#), [Chang D](#), [Roth JA](#), [Wu X](#). Genetic variations in the regulator of g-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS One 6(6):e21120, 2011. e-Pub 6/17/2011. PMCID: PMC3117866.
36. [Li Y](#), [Sheu CC](#), [Ye Y](#), [de Andrade M](#), [Wang L](#), [Chang SC](#), [Aubry MC](#), [Aakre JA](#), [Allen MS](#), [Chen F](#), [Cunningham JM](#), [Deschamps C](#), [Jiang R](#), [Lin J](#), [Marks RS](#), [Pankratz VS](#), [Su L](#), [Li Y](#), [Sun Z](#), [Tang H](#), [Vasmatzis G](#), [Harris CC](#), [Spitz MR](#), [Jen J](#), [Wang R](#), [Zhang ZF](#), [Christiani DC](#), [Wu X](#), [Yang P](#). Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 11(4):321-30, 4/2010. e-Pub 3/2010. PMCID: PMC2945218.
37. [Hildebrandt MA](#), [Yang H](#), [Hung MC](#), [Izzo JG](#), [Huang M](#), [Lin J](#), [Ajani JA](#), [Wu X](#). Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy. J Clin Oncol 27(6):857-71, 2/2009. e-Pub 1/2009. PMCID: PMC2738430.
38. [Wu X](#), [Ye Y](#), [Kiemenev LA](#), [Sulem P](#), [Rafnar T](#), [Matullo G](#), [Seminara D](#), [Yoshida T](#), [Saeki N](#), [Andrew AS](#), [Dinney CP](#), [Czerniak B](#), [Zhang ZF](#), [Kiltie AE](#), [Bishop DT](#), [Vineis P](#), [Porru S](#), [Buntinx F](#), [Kellen E](#), [Zeegers MP](#), [Kumar R](#), [Rudnai P](#), [Gurzau E](#), [Koppova K](#), [Mayordomo JL](#), [Sanchez M](#), [Saez B](#), [Lindblom A](#), [de Verdier P](#), [Steineck G](#), [Mills GB](#), [Schned A](#), [Guarnera S](#), [Polidoro S](#), [Chang SC](#), [Lin J](#), [Chang DW](#), [Hale KS](#), [Majewski T](#), [Grossman HB](#), [Thorlacius S](#), [Thorsteinsdottir U](#), [Aben KK](#), [Witjes JA](#), [Stefansson K](#), [Amos CI](#), [Karagas MR](#), [Gu J](#). Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 41(9):991-5, 2009. e-Pub 8/2009. PMID: 19648920.
39. [Spitz MR](#), [Amos CI](#), [Dong Q](#), [Lin J](#), [Wu X](#). The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst 100(21):1552-6, 11/2008. e-Pub 10/2008. PMCID: PMC2720751.
40. [Xing J](#), [Chen M](#), [Wood CG](#), [Lin J](#), [Spitz MR](#), [Ma J](#), [Amos CI](#), [Shields PG](#), [Benowitz NL](#), [Gu J](#), [de Andrade M](#), [Swan GE](#), [Wu X](#). Mitochondrial DNA Content: Its Genetic Heritability and Association with Renal Cell Carcinoma. J Natl Cancer Inst 100(15):1104-12, 8/2008. e-Pub 7/2008. PMCID: PMC2720693.
41. [Reyes-Gibby CC](#), [Wu X](#), [Spitz M](#), [Kurzrock R](#), [Fisch M](#), [Bruera E](#), [Shete S](#). Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 9(8):777-85, 8/2008. PMID: 18672213.
42. [Amos CI](#), [Wu X](#), [Broderick P](#), [Gorlov IP](#), [Gu J](#), [Eisen T](#), [Dong Q](#), [Zhang Q](#), [Gu X](#), [Vijayakrishnan J](#), [Sullivan K](#), [Matakidou A](#), [Wang Y](#), [Mills G](#), [Doheny K](#), [Tsai YY](#), [Chen WV](#), [Shete S](#), [Spitz MR](#), [Houlston RS](#). Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40(5):616-22, 5/2008. e-Pub 4/2008. PMCID: PMC2713680.
43. [Yang H](#), [Gu J](#), [Lin X](#), [Grossman HB](#), [Ye Y](#), [Dinney CP](#), [Wu X](#). Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 14(7):2236-44, 4/2008. PMID: 18381966.
44. [Wu X](#), [Lin J](#), [Grossman HB](#), [Huang M](#), [Gu J](#), [Eitzel CJ](#), [Amos CI](#), [Dinney CP](#), [Spitz MR](#). Projecting Individualized Probabilities of Developing Bladder Cancer in Caucasians. J Clin Oncol 25(31):4974-81, 11/2007. PMID: 17971596.
45. [Wu X](#), [Lin J](#), [Eitzel CJ](#), [Dong Q](#), [Gorlova OY](#), [Zhang Q](#), [Amos CI](#), [Spitz MR](#). Interplay between mutagen sensitivity and epidemiological factors in modulating lung cancer risk. Int J Cancer 120(12):2687-95, 6/2007. PMID:

46. [CI](#). A risk model for prediction of lung cancer. *J Natl Cancer Inst* 99(9):715-26, 5/2007. PMID: 17470739.
47. [Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, Gu J, Grossman HB, Wu X](#). Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. *Clin Cancer Res* 13(9):2614-20, 5/2007. PMID: 17473191.
48. **Wu X**, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. *Am J Hum Genet* 78(3):464-79, 2006. PMID: 16465622.
49. **Wu X**, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. *J Clin Oncol* 24(23):3789-98, 2006. PMID: 16785472.
50. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, **Wu X**. Matrix metalloproteinase polymorphisms and bladder cancer risk. *Cancer Res* 66(24):11644-8, 2006. PMID: 17178858.
51. **Wu X**, Spitz MR, Amos CI, Lin J, Shao L, Gu J, de Andrade M, Benowitz NL, Shields PG, Swan GE. Mutagen sensitivity has high heritability: evidence from a twin study. *Cancer Res* 66(12):5993-6, 2006. PMID: 16778168.
52. Lin J, Kadlubar FF, Spitz MR, Zhao H, **Wu X**. A modified host cell reactivation assay to measure DNA repair capacity for removing 4-aminobiphenyl adducts: a pilot study of bladder cancer. *Cancer Epidemiol Biomarkers Prev* 14(7):1832-6, 2005. PMID: 16030125.
53. Saldivar SJ, Wang Y, Zhao H, Shao L, Lin J, Spitz MR, **Wu X**. An association between a NQO1 genetic polymorphism and risk of lung cancer. *Mutat Res* 582(1-2):71-8, 2005. PMID: 15781212.
54. Schabath MB, Spitz MR, Lerner SP, Pillow PC, Hernandez LM, Delclos GL, Grossman HB, **Wu X**. Case-control analysis of dietary folate and risk of bladder cancer. *Nutr Cancer* 53(2):144-51, 2005. PMID: 16573375.
55. Schabath MB, Hernandez LM, **Wu X**, Pillow PC, Spitz MR. Dietary phytoestrogens and lung cancer risk. *JAMA* 294(12):1493-504, 2005. PMID: 16189362.
56. Gu J, Liang D, Wang Y, Lu C, **Wu X**. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. *Mutat Res* 581(1-2):97-104, 2005. PMID: 15725609.
57. Zhao H, Liang D, Grossman HB, **Wu X**. Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. *Urology* 66(4):769-74, 2005. PMID: 16230136.
58. Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, **Wu X**. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. *Clin Cancer Res* 11(8):2894-8, 2005. PMID: 15837739.
59. Zhao H, Grossman HB, Delclos GL, Hwang LY, Troisi CL, Chamberlain RM, Chenoweth MA, Zhang H, Spitz MR, **Wu X**. Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation to recurrence. *Cancer* 104(1):30-5, 2005. PMID: 15912517.
60. Shaw AD, Vaporciyan AA, **Wu X**, King TM, Spitz MR, Putnam JB, Dickey BF. Inflammatory gene polymorphisms influence risk of postoperative morbidity after lung resection. *Ann Thorac Surg* 79(5):1704-10, 2005. PMID: 15854959.
61. Komaki R, Chang JY, **Wu X**, Allen PK, Milas L, Liao Z, Fossella FV, Travis E, Spitz MR. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. *Semin Oncol* 32(2 Suppl 3):S92-8, 2005. PMID: 16015542.
62. Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, Grossman HB, **Wu X**. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. *Clin Cancer Res* 11(4):1408-15,

63. [Dong Q, Grossman HB, Spitz MR, Schabath MB, Lerner SP, Wang Y, Day, Dong Q, Wu X.](#) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. *J Clin Oncol* 23(24):5746-56, 2005. PMID: 16110031.
64. Berman DM, Wang Y, Liu Z, Dong Q, Burke LA, Liotta LA, Fisher R, **Wu X.** A functional polymorphism in RGS6 modulates the risk of bladder cancer. *Cancer Res* 64(18):6820-6, 2004. PMID: 15375002.
65. Zhu Y, Spitz MR, Amos CI, Lin J, Schabath MB, **Wu X.** An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. *Cancer Res* 64(6):2251-7, 2004. PMID: 15026370.
66. Hazra A, Grossman HB, Zhu Y, Luo S, Spitz MR, **Wu X.** Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. *Genes Chromosomes Cancer* 41(4):330-8, 2004. PMID: 15390186.
67. Xu H, **Wu X,** Spitz MR, Shete S. Comparison of haplotype inference methods using genotypic data from unrelated individuals. *Hum Hered* 58(2):63-8, 2004. PMID: 15711085.
68. Schabath MB, Grossman HB, Delclos GL, Hernandez LM, Day RS, Davis BR, Lerner SP, Spitz MR, **Wu X.** Dietary carotenoids and genetic instability modify bladder cancer risk. *J Nutr* 134(12):3362-9, 2004. PMID: 15570038.
69. Schabath MB, **Wu X,** Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. *Clin Cancer Res* 10(1 Pt 1):113-23, 2004. PMID: 14734459.
70. [Do KA, Johnson MM, Lee JJ, Wu X, Dong Q, Hong WK, Khuri FR, Spitz MR.](#) Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. *Cancer* 101:2837-42, 2004. PMID: 15536619.
71. Zhu Y, Spitz MR, Zhang H, Grossman HB, Frazier ML, **Wu X.** Methyl-CpG-binding domain 2: a protective role in bladder carcinoma. *Cancer* 100(9):1853-8, 2004. PMID: 15112265.
72. Schabath MB, Delclos GL, Grossman HB, Wang Y, Lerner SP, Chamberlain RM, Spitz MR, **Wu X.** Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. *Cancer Epidemiol Biomarkers Prev* 14(4):878-84, 2004. PMID: 15824159.
73. Lin J, Spitz MR, Wang Y, Schabath MB, Gorlov IP, Hernandez LM, Pillow PC, Grossman HB, **Wu X.** Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. *Carcinogenesis* 25(9):1639-47, 2004. PMID: 15117811.
74. [Franco EL, Correa P, Santella RM, Wu X, Goodman SN, Petersen GM.](#) Role and limitations of epidemiology in establishing a causal association. *Semin Cancer Biol* 14:413-26, 2004. PMID: 15489134.
75. **Wu X,** Zhao H, Do KA, Johnson MM, Dong Q, Hong WK, Spitz MR. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. *Clin Cancer Res* 10(12 Pt 1):3988-95, 2004. PMID: 15217929.
76. Shao L, Lerner SL, Bondaruk J, Czerniak BA, Zeng X, Grossman HB, Spitz MR, **Wu X.** Specific chromosome aberrations in peripheral blood lymphocytes are associated with risk of bladder cancer. *Genes Chromosomes Cancer* 41(4):379-89, 2004. PMID: 15390184.
77. [Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X.](#) An association between NQO1 genetic polymorphism and risk of bladder cancer. *Mutat Res* 536(1-2):131-7, 4/2003. PMID: 12694753.
78. **Wu X,** Yu H, Makan N, Spitz MR. Assessment of insulin-like growth factors and mutagen sensitivity as predictors of lung cancer risk. *Methods Mol Med* 75:279-87, 2003. PMID: 12407747.
79. Wang Y, Spitz MR, Schabath MB, Ali-Osman F, Mata H, **Wu X.** Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. *Lung Cancer* 40(1):25-32, 2003. PMID:

receptor 4 and bladder cancer risk. *Cancer Res* 63:1157-9, 2003. PMID: 12649168.

81. Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S, **Wu X**. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. *DNA Repair (Amst)* 2(8):901-8, 2003. PMID: 12893086.

82. Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, **Wu X**. Genetic instability in bladder cancer assessed by the comet assay. *J Natl Cancer Inst* 95(7):540-7, 2003. PMID: 12671022.

83. Gorlova OY, Amos C, Henschke C, Lei L, Spitz M, Wei Q, **Wu X**, Kimmel M. Genetic susceptibility for lung cancer: interactions with gender and smoking history and impact on early detection policies. *Hum Hered* 56(1-3):139-45, 2003. PMID: 14614248.

84. **Wu X**, Schabath MB, Spitz MR. Myeloperoxidase promoter region polymorphism and lung cancer risk. *Methods Mol Med* 75:121-33, 2003. PMID: 12407737.

85. Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, **Wu X**. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. *J Urol* 169(2):714-7, 2003. PMID: 12544349.

86. [Do KA](#), [Johnson MM](#), [Doherty DA](#), [Lee JJ](#), **Wu X**, [Dong Q](#), [Hong WK](#), [Khuri FR](#), [Fu KK](#), [Spitz MR](#). Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). *Cancer Causes Control* 14:131-8, 2003. PMID: 12749718.

87. **Wu X**, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR, Follen M. Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. *Clin Cancer Res* 9(9):3356-61, 2003. PMID: 12960122.

88. Zheng L, Wang Y, Schabath MB, Grossman HB, **Wu X**. Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. *Cancer Lett* 202(1):61-9, 2003. PMID: 14643027.

89. **Wu X**, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, Spitz MR. Telomere dysfunction: a potential cancer predisposition factor. *J Natl Cancer Inst* 95(16):1211-8, 2003. PMID: 12928346.

90. **Wu X**, Zhao H, Wei Q, Amos CI, Zhang K, Guo Z, Qiao Y, Hong WK, Spitz MR. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. *Carcinogenesis* 24(3):505-9, 2003. PMID: 12663511.

91. Wang Y, Liang D, Spitz MR, Zhang K, Dong Q, Amos CI, **Wu X**. XRCC3 genetic polymorphism, smoking, and lung carcinoma risk in minority populations. *Cancer* 98(8):1701-6, 2003. PMID: 14534887.

92. [Zhu Y](#), [Spitz MR](#), [Strom S](#), [Tomlinson GE](#), [Amos CI](#), [Minna JD](#), **Wu X**. A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer. *Int J Cancer* 102(5):536-40, 12/2002. PMID: 12432559.

93. [Spitz MR](#), [Barnett MJ](#), [Goodman GE](#), [Thorndquist MD](#), **Wu X**, [Pollak M](#). Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. *Cancer Epidemiol Biomarkers Prev* 11(11):1413-8, 11/2002. PMID: 12433720.

94. [Zhu Y](#), [Spitz MR](#), [Zheng YL](#), [Hong WK](#), **Wu X**. BPDE-induced lymphocytic 3p21.3 aberrations may predict head and neck carcinoma risk. *Cancer* 95(3):563-8, 8/2002. PMID: 12209748.

95. [Chang S](#), **Wu X**, [Yu H](#), [Spitz MR](#). Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. *Cancer Epidemiol Biomarkers Prev* 11(8):758-66, 8/2002. PMID: 12163330.

96. [Schabath MB](#), [Spitz MR](#), [Hong WK](#), [Delclos GL](#), [Reynolds WF](#), [Gunn GB](#), [Whitehead LW](#), **Wu X**. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. *Lung Cancer* 37(1):35-40, 7/2002. PMID: 12057865.

- (MPO) genotypes, and lung cancer risk. *Am J Ind Med* 42(1):29-37, 1/2002. PMID: 12111688.
98. [Zhu Y](#), [Spitz MR](#), [Hsu TC](#), [Wu X](#). Genetic instability of specific chromosomes associated with a family history of cancer. *Cancer Genet Cytogenet* 136(1):73-7, 7/2002. PMID: 12165456.
 99. [Wu X](#), [Lippman SM](#), [Lee JJ](#), [Zhu Y](#), [Wei QV](#), [Thomas M](#), [Hong WK](#), [Spitz MR](#). Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. *Cancer Res* 62(10):2813-8, 5/2002. PMID: 12019158.
 100. [Wu X](#), [Zhao H](#), [Amos CI](#), [Shete S](#), [Makan N](#), [Hong WK](#), [Kadlubar FF](#), [Spitz MR](#). p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. *J Natl Cancer Inst* 94(9):681-90, 5/2002. PMID: 11983757.
 101. [Buchholz TA](#), [Wu X](#), [Hussain A](#), [Tucker SL](#), [Mills GB](#), [Haffty B](#), [Bergh S](#), [Story M](#), [Geara FB](#), [Brock WA](#). Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. *Int J Cancer* 97(5):557-61, 2/2002. PMID: 11807777.
 102. [Zhao H](#), [Spitz MR](#), [Gwyn KM](#), [Wu X](#). Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. *Mol Carcinog* 33(2):99-104, 2/2002. PMID: 11813302.
 103. [Wang Y](#), [Spitz MR](#), [Tsou AM](#), [Zhang K](#), [Makan N](#), [Wu X](#). Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. *Lung Cancer* 35(2):137-42, 2/2002. PMID: 11804685.
 104. [Zhang H](#), [Spitz MR](#), [Tomlinson GE](#), [Schabath MB](#), [Minna JD](#), [Wu X](#). Modification of lung cancer susceptibility by green tea extract as measured by the comet assay. *Cancer Detect Prev* 26(6):411-8, 2002. PMID: 12507225.
 105. [Zhu Y](#), [Spitz MR](#), [Lei L](#), [Mills GB](#), [Wu X](#). A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. *Cancer Res* 61:7825-9, 2001. PMID: 11691799.
 106. [Zhao H](#), [Spitz MR](#), [Tomlinson GE](#), [Zhang H](#), [Minna JD](#), [Wu X](#). Gamma-radiation-induced G2 delay, apoptosis, and p53 response as potential susceptibility markers for lung cancer. *Cancer Res* 61:7819-24, 2001. PMID: 11691798.
 107. [Spitz MR](#), [Wu X](#), [Wang Y](#), [Wang LE](#), [Shete S](#), [Amos CI](#), [Guo Z](#), [Lei L](#), [Mohrenweiser H](#), [Wei Q](#). Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. *Cancer Res* 61:1354-7, 2001. PMID: 11245433.
 108. [Buchholz TA](#), [Wu X](#). Radiation-induced chromatid breaks as a predictor of breast cancer risk. *Int J Radiat Oncol Biol Phys* 49:533-7, 2001. PMID: 11173151.
 109. [Wu X](#), [Gwyn K](#), [Amos CI](#), [Makan N](#), [Hong WK](#), [Spitz MR](#). The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. *Carcinogenesis* 22:923-8, 2001. PMID: 11375900.
 110. [Zhang H](#), [Buchholz TA](#), [Hancock D](#), [Spitz MR](#), [Wu X](#). Gamma-radiation-induced single cell DNA damage as a measure of susceptibility to lung cancer: A preliminary report. *Int J Oncol* 17(2):399-404, 8/2000. PMID: 10891553.
 111. [Vulimiri SV](#), [Wu X](#), [Baer-Dubowska W](#), [Andrade Md](#), [Detry M](#), [Spitz MR](#), [DiGiovanni J](#). Analysis of aromatic DNA adducts and 7,8-dihydro-8-oxo-2'-deoxyguanosine in lymphocyte DNA from a case-control study of lung cancer involving minority populations. *Mol Carcinog* 27:330, 2000. PMID: 10747297.
 112. [Wu X](#), [Hudmon KS](#), [Detry MA](#), [Chamberlain RM](#), [Spitz MR](#). D2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: a lung cancer case-control study. *Cancer Epidemiol Biomarkers Prev* 9:1021-6, 2000. PMID: 11045783.
 113. [Spitz MR](#), [Duphorne CM](#), [Detry MA](#), [Pillow PC](#), [Amos CI](#), [Lei L](#), [de Andrade M](#), [Gu X](#), [Hong WK](#), [Wu X](#). Dietary intake of isothiocyanates: evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk.

- myeloperoxidase and lung cancer risk. *Carcinogenesis* 21:1163-6, 2000. PMID: 10837005.
115. [Wu X](#), [Yu H](#), [Amos CI](#), [Hong WK](#), [Spitz MR](#). Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. *J Natl Cancer Inst* 92:737-43, 2000. PMID: 10984281.
116. [de Andrade M](#), [Spitz MR](#), [Wu X](#), [Liang JC](#), [Strom SS](#). Statistical models for analysis of cytogenetic biomarkers. *J Investig Med* 48:281-6, 2000. PMID: 10916287.
117. Spitz, M, Detry M, Pillow P, Hu Y, Amos C, Hong W, [Wu X](#) . Variant alleles of the D2 dopamine receptor gene and obesity. *Nutr Res* 20(3):371-380, 2000.
118. [Wu X](#), [Kemp B](#), [Amos CI](#), [Honn SE](#), [Zhang W](#), [Walsh GL](#), [Spitz MR](#). Associations among telomerase activity, p53 protein overexpression, and genetic instability in lung cancer. *Br J Cancer* 80:453-7, 1999. PMID: 10408853.
119. [Gu J](#), [Spitz MR](#), [Yang F](#), [Wu X](#). Ethnic differences in poly(ADP-ribose) polymerase pseudogene genotype distribution and association with lung cancer risk. *Carcinogenesis* 20:1465-9, 1999. PMID: 10426793.
120. [Spitz MR](#), [Wei O](#), [Li G](#), [Wu X](#). Genetic susceptibility to tobacco carcinogenesis. *Cancer Invest* 17(8):645-59, 1999. PMID: 10592771.
121. [Yu H](#), [Spitz MR](#), [Mistry J](#), [Gu J](#), [Hong WK](#), [Wu X](#). Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. *J Natl Cancer Inst* 91:151-6, 1999. PMID: 9923856.
122. [Abdel-Rahman SZ](#), [Soliman AS](#), [Bondy ML](#), [Wu X](#), [El-Badawy SA](#), [Mahgoub KG](#), [Ismail S](#), [Seifeldin IA](#), [Levin B](#). Polymorphism of glutathione S-transferase loci GSTM1 and GSTT1 and susceptibility to colorectal cancer in Egypt. *Cancer Lett* 142:97-104, 1999. PMID: 10424787.
123. [Gu J](#), [Bondy ML](#), [Sigurdson A](#), [Spitz MR](#), [Hsu TC](#), [Wu X](#). Three measures of mutagen sensitivity in a cancer-free population. *Cancer Genet Cytogenet* 110:65-9, 1999. PMID: 10198626.
124. [Wu X](#), [Hsu TC](#), [Cao S](#), [Lee JJ](#), [Amos CI](#), [Spitz MR](#). Deletion in poly(ADP-ribose) polymerase pseudogene and lung cancer risk. *Carcinogenesis* 19(1):1393-1399, 1/1998. PMID: 9472699.
125. [Wu X](#), [Gu J](#), [Amos CI](#), [Jiang H](#), [Hong WK](#), [Spitz MR](#). A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls. *Cancer* 83:1118-27, 1998. PMID: 9740076.
126. [Lin H](#), [Bondy ML](#), [Langford LA](#), [Hess KR](#), [Delclos GL](#), [Wu X](#), [Chan W](#), [Pershouse MA](#), [Yung WK](#), [Steck PA](#). Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. *Clin Cancer Res* 4:2447-54, 1998. PMID: 9796977.
127. [Wu X](#), [Gu J](#), [Hong WK](#), [Lee JJ](#), [Amos CI](#), [Jiang H](#), [Winn RJ](#), [Fu KK](#), [Cooper J](#), [Spitz MR](#). Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. *J Natl Cancer Inst* 90:1393-9, 1998. PMID: 9747870.
128. [Wu X](#), [Zhao Y](#), [Honn SE](#), [Tomlinson GE](#), [Minna JD](#), [Hong WK](#), [Spitz MR](#). Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. *Cancer Res* 58:1605-8, 1998. PMID: 9563468.
129. [Spitz MR](#), [Shi H](#), [Yang F](#), [Hudmon KS](#), [Jiang H](#), [Chamberlain RM](#), [Amos CI](#), [Wan Y](#), [Cinciripini P](#), [Hong WK](#), [Wu X](#). Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. *J Natl Cancer Inst* 90:358-63, 1998. PMID: 9498485.
130. [Wu X](#), [Zhao Y](#), [Kemp BL](#), [Amos CI](#), [Siciliano MJ](#), [Spitz MR](#). Chromosome 5 aberrations and genetic predisposition to lung cancer. *Int J Cancer* 79:490-3, 1998. PMID: 9761118.
131. [Wu X](#), [Amos CI](#), [Kemp BL](#), [Shi H](#), [Jiang H](#), [Wan Y](#), [Spitz MR](#). Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. *Cancer Epidemiol Biomarkers Prev* 7(1):13-8, 1998. PMID: 9456237.

- Cancer Epidemiol Biomarkers Prev 7:567-70, 1996. PMID: 9061923.
133. [King TM](#), [Trizna Z](#), [Wu X](#), [Amos CI](#), [Fueger RH](#), [Fueger JJ](#), [Fritsche HA](#), [Hsu TC](#), [Winn R](#), [Spitz MR](#). A clinical trial to evaluate the effect of vitamin C supplementation on in vitro mutagen sensitivity. The University of Texas M. D. Anderson Clinical Community Oncology Program Network. Cancer Epidemiol Biomarkers Prev 6:537-42, 1997. PMID: 9232342.
 134. [Wu X](#), [Shi H](#), [Jiang H](#), [Kemp B](#), [Hong WK](#), [Delclos GL](#), [Spitz MR](#). Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 18:967-73, 1997. PMID: 9163682.
 135. [Wu X](#), [Dave BJ](#), [Jiang H](#), [Pathak S](#), [Spitz MR](#). Lung carcinoma patients with a family history of cancer and lymphocyte primary chromosome 9 aberrations. Cancer 79:1527-32, 1997. PMID: 9118034.
 136. [Spitz MR](#), [Wu X](#), [Jiang H](#), [Hsu TC](#). Mutagen sensitivity as a marker of cancer susceptibility. J Cell Biochem Suppl 25:80-4, 1996. PMID: 9027602.
 137. [Wu X](#), [Hsu TC](#), [Spitz MR](#). Mutagen sensitivity exhibits a dose-response relationship in case-control studies. Cancer Epidemiol Biomarkers Prev 5:577-8, 1996. PMID: 8827363.
 138. [Hsu TC](#), [Wu X](#), [Trizna Z](#). Mutagen sensitivity in humans. A comparison between two nomenclature systems for recording chromatid breaks. Cancer Genet Cytogenet 87:127-32, 1996. PMID: 8625258.
 139. [Wu X](#), [Spitz MR](#), [Delclos GL](#), [Connor TH](#), [Zhao Y](#), [Siciliano MJ](#), [Hsu TC](#). Survival of cells with bleomycin-induced chromosomal lesions in the cultured lymphocytes of lung cancer patients. Cancer Epidemiol Biomarkers Prev 5:527-32, 1996. PMID: 8827357.
 140. [Wu X](#), [Delclos GL](#), [Annegers JF](#), [Bondy ML](#), [Honn SE](#), [Henry B](#), [Hsu TC](#), [Spitz MR](#). A case-control study of wood dust exposure, mutagen sensitivity, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 4(6):583-8, 9/1995. PMID: 8547823.
 141. [Wu X](#), [Hsu TC](#), [Annegers JF](#), [Amos CI](#), [Fueger JJ](#), [Spitz MR](#). A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer cases. Cancer Res 55(3):557-61, 2/1995. PMID: 7530597.
 142. [Jin X](#), [Wu X](#), [Roth JA](#), [Amos CI](#), [King TM](#), [Branch C](#), [Honn SE](#), [Spitz MR](#). Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16:2205-8, 1995. PMID: 7554076.
 143. [Strom SS](#), [Wu X](#), [Sigurdson AJ](#), [Hsu TC](#), [Fueger JJ](#), [Lopez J](#), [Tee PG](#), [Spitz MR](#). Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans. J Natl Cancer Inst Monogr 18(18):29-33, 1995. PMID: 8562219.
 144. [Spitz MR](#), [Hsu TC](#), [Wu X](#), [Fueger JJ](#), [Amos CI](#), [Roth JA](#). Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 4:99-103, 1995. PMID: 7537995.
 145. [Wu X](#), [Hong C](#). Application of the method of measuring cellular ATP on the research of pneumoconiosis. J Occup Med 17:231-232, 1990.
 146. [Wu X](#), [He L](#), [Hong C](#). Preventive efficacy of a Chinese traditional medicine anti-silicosis tablet on silicosis. Zhejiang Acad Med Science, 1990.
 147. [Wu X](#), [Zhang QF](#). The effects of zinc on the alveolar macrophage cytotoxicity due to Ni-coal dust. Chin Med J (Engl) 103:754-8, 1990. PMID: 2123777.

Invited Articles

1. [Wu X](#), [Lu C](#), [Chiang SS](#), [Ajani JA](#). Pharmacogenetics in esophageal cancer. Semin Oncol 32(6 Suppl 9):S87-9, 12/2005. PMID: 16399440.
2. [Spitz MR](#), [Wu X](#), [Mills G](#). Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23(2):267-75, 2005. PMID: 15637390.

15324694.

4. [Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B.](#) Focus on bladder cancer. Cancer Cell 6:111-6, 2004. PMID: 15324694.

Last updated: 2/18/2013

© 2010 The University of Texas M. D. Anderson Cancer Center